What does the UK’s pro-innovation approach to AI mean for life sciences companies?

It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

EU court under pressure to define SPC limits in patent row

24 April 2026 An opinion has put pressure on the CJEU to clarify a long-running grey area that could change the game for how drug makers secure supplementary protection certificates across Europe.

Europe

INTA 2026: In-house tips on what to do in London

21 April 2026 With the start of the first-ever INTA Annual Meeting held in the UK capital just weeks away, in-house IP counsel share their favourite ways to spend downtime in the city.

Europe

IP finance gap risks startup exodus, EUIPO warns

13 April 2026 New report finds that just 13% of IP-owning firms have sought financing through their assets, with billions in potential funding left untapped, as structural barriers persist.

More features

EU court under pressure to define SPC limits in patent row

Squires refuses to resurrect HydraFacial patent review

Litigator from Brown Rudnick moves firms to chair practice

INTA 2026: In-house tips on what to do in London

Simmons & Simmons makes senior Asia trademark hire

Baker McKenzie strengthens IP bench with new German lead

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

IP finance gap risks startup exodus, EUIPO warns

What does the UK’s pro-innovation approach to AI mean for life sciences companies?

More on this story

Editor's picks

Editor's picks

More features